Trevi Therapeutics Statistics
Total Valuation
TRVI has a market cap or net worth of $220.68 million. The enterprise value is $152.38 million.
Important Dates
The next confirmed earnings date is Wednesday, November 6, 2024, after market close.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TRVI has 72.59 million shares outstanding. The number of shares has increased by 9.43% in one year.
| Current Share Class | 72.59M |
| Shares Outstanding | 72.59M |
| Shares Change (YoY) | +9.43% |
| Shares Change (QoQ) | +1.53% |
| Owned by Insiders (%) | 1.26% |
| Owned by Institutions (%) | 37.25% |
| Float | 43.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.33 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.68, with a Debt / Equity ratio of 0.02.
| Current Ratio | 10.68 |
| Quick Ratio | 10.29 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4,797.00 |
Financial Efficiency
Return on equity (ROE) is -48.09% and return on invested capital (ROIC) is -32.92%.
| Return on Equity (ROE) | -48.09% |
| Return on Assets (ROA) | -30.88% |
| Return on Capital (ROIC) | -32.92% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.55M |
| Employee Count | 25 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -11,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +90.00% in the last 52 weeks. The beta is 1.01, so TRVI's price volatility has been similar to the market average.
| Beta (5Y) | 1.01 |
| 52-Week Price Change | +90.00% |
| 50-Day Moving Average | 3.15 |
| 200-Day Moving Average | 2.81 |
| Relative Strength Index (RSI) | 46.51 |
| Average Volume (20 Days) | 494,812 |
Short Selling Information
The latest short interest is 1.52 million, so 2.10% of the outstanding shares have been sold short.
| Short Interest | 1.52M |
| Short Previous Month | 1.51M |
| Short % of Shares Out | 2.10% |
| Short % of Float | 3.50% |
| Short Ratio (days to cover) | 3.53 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -43.17M |
| Pretax Income | -38.78M |
| Net Income | -38.77M |
| EBITDA | -43.03M |
| EBIT | -43.17M |
| Earnings Per Share (EPS) | -$0.39 |
Full Income StatementBalance Sheet
The company has $69.50 million in cash and $1.19 million in debt, giving a net cash position of $68.30 million or $0.94 per share.
| Cash & Cash Equivalents | 69.50M |
| Total Debt | 1.19M |
| Net Cash | 68.30M |
| Net Cash Per Share | $0.94 |
| Equity (Book Value) | 66.17M |
| Book Value Per Share | 0.91 |
| Working Capital | 65.38M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$32.79 million and capital expenditures -$68,000, giving a free cash flow of -$32.86 million.
| Operating Cash Flow | -32.79M |
| Capital Expenditures | -68,000 |
| Free Cash Flow | -32.86M |
| FCF Per Share | -$0.45 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |